The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.The company’s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.Also Read: Moderna’s mRNA Flu Vaccine Outperforms Standard Shots“COVID-19 continues to pose a significant potential t ...